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that induce long-lasting protection (Olsson et al., 2007). It is
not known what level of antibodies indicates an individual’s
ability to fend off HPV infection, but the available data do
suggest that HPV vaccines would provide a lengthy period of
protection, likely to usher a vaccinated individual through
the years of highest infection risk and beyond. Additional
studies are ongoing to verify these projections. Based on
demonstrated clinical efﬁcacy and favorable safety proﬁle,
this quadrivalent HPV prophylactic vaccine is being intro-
duced as a cost-effective means for reducing the morbidity
and mortality of cervical/anogenital cancers, as well as the
emotional and economic burdens of abnormal Pap tests and
genital warts. Compared to a vaccine containing VLPs of only
HPV types 16 and 18, the reduction of HPV-associated dis-
ease burden is anticipated to be signiﬁcantly higher with the
administration of the quadrivalent HPV vaccine, since HPV 6
and 11 are responsible for approximately 90% of all genital
warts and 15% of low-grade cervical neoplasias. The quadri-
valent HPV vaccine is the ﬁrst and only to show 100% efﬁcacy
against HPV 6, 11, 16 and 18-related external genital lesions
including genital warts, vulvar and vaginal cancers. More-
over, the prevention and cost-savings from HPV 6/11 related
diseases will begin relatively early in the ﬁrst years follow-
ing vaccine introduction making the quadrivalent vaccine
particularly attractive to national policy-makers.
doi:10.1016/j.ijid.2008.05.085
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Global Use of Seasonal Inﬂuenza Vaccine
D.S. Fedson
Sergy Haut, France
For several years, the Macroepidemiology of Inﬂuenza Vac-
cination Study Group (MIVSG) has documented inﬂuenza
vaccine distribution, recommendations and reimbursement
in an increasing number of countries throughout the world.
In 2003, 56 MIVSG countries used 275 million (M) doses,
94% of the 292M doses distributed worldwide. By 2005, the
MIVSG had grown to include 73 countries. These countries
used approximately 330M doses of seasonal vaccine. In most
countries, levels of vaccine use (doses distributed/1000
total population) showed relatively little change between
2002, the year before the re-emergence of H5N1 inﬂuenza,
and 2005, although large differences persisted between
individual countries. However, six countries (Belgium, El
Salvador, Japan, Latvia, Malta and Mexico) showed substan-
tial increases in vaccine use over this period, and Malta’s
increase from 124 to 657 doses/1000 was remarkable. In a
few countries, vaccine use decreased, sometimes due to
supply shortages. Some form of public reimbursement for
vaccination was provided in approximately 60% of the sur-
veyed countries, and they tended to have higher levels of
vaccine use compared with countries with no public reim-
bursement. Vaccination recommendations for risk groups
showed little change compared with earlier years, although
the age cut-off levels for vaccinating older adults decreased
in several countries. More interesting, by 2005, seven coun-
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ries had adopted policies for vaccinating children 6-23
onths in age. In the US, the upper age limit for children
as extended to 5 years in 2006 and to 18 years in 2008.
In 2005, nine vaccine-producing countries used 59% of
ll doses of seasonal inﬂuenza vaccine, but had only 12%
f the world’s population. Inﬂuenza vaccination is gradually
ncreasing in many countries, especially in those with rapidly
eveloping economies. This growth in seasonal vaccine use
ill lay the foundation for vaccination programs when the
ext pandemic occurs.
oi:10.1016/j.ijid.2008.05.086
9.002
he Potential Beneﬁts of Intradermal Vaccination
.J. Ward
McGill University Health Center, Montreal, Canada
he intradermal (ID) route of immunization has a fair claim
o primacy since the smallpox vaccine was administered via
he skin for almost 100 years before the next human vaccine
as introduced. Despite this early success and long-standing
mmunological interest in this route, the large majority of
urrent vaccines are administered either via the intramus-
ular or subcutaneous routes. The accessibility of the skin
s obvious and the potential immunological advantages of ID
mmunization have been known for some time. Animal mod-
ls of ID vaccination have generally yielded excellent results
ith a range of microbial antigens and several ID vaccines
ave been successfully introduced for human infections such
s rabies and hepatitis B. The skin is the largest immune
organ’ of the human body and, unlike subcutaneous and
uscle tissues, the skin has evolved speciﬁcally to limit the
enetration of chemical andmicroorganisms. As a result, the
kin is better prepared than most tissues to actively screen
or invasive microbes and to mount appropriate innate and
daptive immune responses. The immunologic characteris-
ics and capabilities of the skin have been the subject of
onsiderable research for many years due to this unique
front line’ position. Until recently however, full exploita-
ion of the potential of the ID route for vaccination has been
ampered by the lack of simple, reliable and safe injection
ystems. Recent advances in delivery system technologies
ave sparked renewed interest in the ID route for both
stablished and new vaccines. This presentation will provide
n overview of the potential immunological and practical
dvantages of ID vaccination as well as a brief review of
istorical and recent ID vaccination techniques.
oi:10.1016/j.ijid.2008.05.087
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linical Development of a Seasonal Inﬂuenza Vaccine by
ntradermal Micro-injection
. SavilleSanoﬁ Pasteur, Marcy l’Etoile, France
ackground: Annual trivalent inactivated inﬂuenza vaccines
TIV) provide protection for hundreds of millions of individu-
ls worldwide. Yet there is need to improve vaccine efﬁcacy
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or the elderly who are most affected by inﬂuenza, and to
ncrease vaccine coverage in younger adults. The intrader-
al route of vaccination provides a direct and potentially
ore efﬁcient access to the immune system. An ID TIV
as developed with a unique, convenient microinjection
ystem, and 2 dosage presentations speciﬁcally for elderly
nd younger adults (respectively 15g or 9g hemagglu-
inin/strain/dose).
Methods: The immunogenicity and safety of the two
resentations of ID TIV have been investigated in sev-
ral large-scale Phase 2 and 3 studies in several European
ountries, Australia and New Zealand. In each study, a
icensed intramuscular TIV, (Vaxigrip®; 15g hemagglu-
inin/strain/dose) was used as a control. Safety evaluation
ncluded documentation of solicited and unsolicited reac-
ions. Hemagglutination inhibition responses were evaluated
n D0 and D21.
Results: Phase 2 studies in more than 2000 subjects aged
8—60 years or >60 years have demonstrated that the 15g
D intradermal vaccination induces higher immune responses
ompared with Vaxigrip against all three strains, as assessed
y D21 GMTs and seroprotection rates. Among younger
dults, the 9g intradermal vaccine was demonstrated to
nduce an equivalent immune response to Vaxigrip.
Safety results showed that both ID vaccine presentations
ere well tolerated. When 18—60 year olds, subjects were
accinated a second time either ID or IM, one year after
heir ﬁrst vaccination, reactogenicity was not enhanced
ompared with that observed after the ﬁrst vaccination.
Conclusion: Using microinjection to deliver antigen via
he less-invasive intradermal route, ID TIV was shown to
licit superior immune responses to conventional vaccine in
lderly adults, and provides an alternative vaccine for adults
hat may encourage increased vaccine uptake.
oi:10.1016/j.ijid.2008.05.088
9.004
rom Immunogenicity to Vaccine Efﬁcacy: Insights from
tatistical and Causal Models
.E. Halloran
Department of Biostatistics, Seattle, WA, USA
ackground & Objectives: The identiﬁcation of immunolog-
cal surrogate markers of protection against disease plays
key role in the assessment of the efﬁcacy of any vaccine.
he sole identiﬁcation of an appropriate surrogate marker is
owever not sufﬁcient to provide an accurate prediction of
accine efﬁcacy. A statistical model providing a reliable esti-
ation of the relationship between this marker and clinical
rotection is also required. We review analyses and mod-
ls that explore this relationship in the case of inﬂuenza.
e then discuss the application of such models to estimate
he gain in efﬁcacy provided by a novel seasonal inﬂuenza
accine given by intradermal microinjection.
Methods & Principal ﬁndings: Several markers have been
sed to assess the immunogenicity of inﬂuenza vaccines.
nti-haemagglutinin antibodies, measured by the haemag-
lutination inhibition (HI) assay is however the only one for
hich attempts have been made to quantify its relationship
ith protection against clinical inﬂuenza. Seminal analyses
i
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ocused on the identiﬁcation of an HI titre level that can be
ssociated with either a 50% reduction (1:40) or a 90% reduc-
ion (1:92) in the risk of inﬂuenza. More recently, a model
sing published data from 15 studies, conﬁrmed the signiﬁ-
ant and positive relationship existing between HI titre and
linical protection against inﬂuenza and provided an esti-
ate of the level of protection against inﬂuenza for any
I titer. When applied to immunogenicity data from clinical
rials with an trivalent, inactivate inﬂuenza vaccine given
y intradermal microinjection, this model predicts a gain
n vaccine efﬁcacy of 14% (95% CI: 10—18) compared with
onventional non-adjuvanted inactivated inﬂuenza vaccines
iven intramuscularly.
Conclusions: Statistical models estimating the relation-
hip between HI data and level of protection against
nﬂuenza provide useful information to predict vaccine efﬁ-
acy, particularly for comparing vaccines based on their
mmunological proﬁle.
oi:10.1016/j.ijid.2008.05.089
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reatment of Hepatitis C: Yesterday, Today, and Tomorrow
.R. Reddy
University of Pennsylvania, Philadelphia, PA, USA
pproximately 170 million people world wide are infected
ith Hepatitis C virus (HCV). The therapy of hepatitis C
as gone through various phases of development. In the
arly 90s, therapy was empirical and standard interferon
as given initially for 6 months and then for 12 months. Then
ame along ribavirin, a guanosine analog and an oral drug,
hich administered with interferon improved sustained viro-
ogic response rates and this primarily was achieved by
ecreasing relapse rates. The current standard of care as
herapy for Hepatitis C consists of pegylated interferon-alfa
nd ribavirin. In genotype 1 patients, sustained virologic
esponse rates have been around 40—60% after 48 weeks
f therapy whereas non-1 patients, primarily made up of
enotypes 2 and 3, have an approximate 80% probability
f sustained virology response after 24 weeks of therapy.
lthough treatment duration has traditionally been ﬁxed,
here is a paradigm of virologic response guided therapy
hat has evolved. For rapid virologic responders, charac-
erized as HCV RNA negativity at week 4, reports suggest
hat 12—16 weeks of therapy for genotype 2 patients and 24
eeks of therapy for genotype 1 patients may be adequate.
n contrast, in genotype 1 patients who have a slow response
haracterized by a loss of HCV RNA at week 24, a prolonged
ourse of 72 weeks is the optimal regimen. Despite these
dvances, there is an unmet need for better therapies in the
on-responders, in those with advanced and decompensated
iver disease, in those with a spectrum of special situations
uch as transplantation etc, and those who do not tolerate
nterferon and ribavirin. Thus there is a need for novel ther-
pies with enhanced efﬁcacy, tolerability, and greater ease
f administration.
We now stand at the edge of an exciting phase with
he advent of Speciﬁcally Targeted Antiviral Therapy for
